Stelara (ustekinumab) / J&J, Tanabe Pharma, BMS - LARVOL DELTA

Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study. (PubMed, Sage Open Chronic Dis) - "In CD, ustekinumab had the highest escalation rate (69.1%), compared with infliximab (16.4%), adalimumab (21.2%), and vedolizumab (23.2%). For UC, adalimumab was most frequently escalated (21.8%), followed by tofacitinib (19.5%), ustekinumab (17.9%), and infliximab (10.0%)...Dose escalation is a common occurrence in IBD maintenance therapy, with substantial variation across treatment agents and patient profiles. These findings emphasize the importance of individualized treatment strategies to improve long-term disease control."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Distinct Baseline Molecular Endotypes but Convergent Responses to Ustekinumab in Psoriatic Arthritis: Longitudinal Multi-Omics Analyses from the Randomised MUST Trial (ACR Convergence 2026) - P3 | "PsA is characterized by distinct sex-associated molecular endotypes at baseline. Despite these differences, ustekinumab induced largely convergent molecular responses across sexes, suggesting that sex-related differences in clinical outcomes may reflect baseline disease biology rather than differential pharmacodynamic effects. Pathways associated with super-response may represent candidate mechanisms for treatment stratification and precision medicine approaches in PsA."

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ustekinumab Plus Prednisone Versus Prednisone Alone for Refractory Giant Cell Arteritis: a Randomized Phase IIb Open-Label Trial (ACR Convergence 2026) - P2 | "At inclusion (UST vs control), baseline characteristics were similar: median disease duration was 2.2 vs 1.3 years; the current relapse was the first in 55% vs 59% of patients; and 25% vs 18% had prior immunosuppressive therapy (methotrexate 20% vs 18%; tocilizumab 10% vs 0%). In this first randomized trial of an anti‑IL‑12/23 agent in GCA, UST plus prednisone significantly increased sustained remission at W52 versus prednisone alone in relapsing GCA, with acceptable safety. These findings support a role for IL‑12/23 in GCA and justify a phase III trial, possibly with extended dosing."

Clinical • P2b data • Giant Cell Arteritis • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases • IL12A

Efficacy and Safety of Subcutaneous Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis: Results of the Open-label, Phase 3 PSUMMIT-Jr Study Through Week 52 (ACR Convergence 2026) - No abstract available

Clinical • P3 data • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Pediatrics • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Low Relapse Rates After Discontinuation of Ustekinumab following Long-Term Remission in Giant Cell Arteritis (ACR Convergence 2026) - No abstract available

Clinical • Giant Cell Arteritis • Immunology

Advanced Therapies in IBD: Biologics and Beyond (IASGO 2026) - "Ulcerative colitis: For moderate-to-severe UC, biologic options include anti-TNF agents (infliximab, adalimumab,and golimumab), vedolizumab, ustekinumab, and selective IL-23 inhibitors (mirikizumab,risankizumab, and guselkumab). Small-molecule therapies, including JAK inhibitors (tofacitiniband upadacitinib) and S1P receptor modulators (ozanimod and etrasimod), further expandtherapeutic options...Recent AGA guidance further incorporates newer IL-23inhibitors, including mirikizumab and guselkumab, and upadacitinib into the expandingtherapeutic armamentarium. Overall, contemporary IBD management is shifting from rigid treatment algorithms toward early,individualized selection of advanced therapies, integrating efficacy, safety, disease phenotype, priortreatment exposure, and patient preference."

Metastases • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

Optimizing Biologic Therapy between Gastroenterologists and Surgeons for Long-term Remission (IASGO 2026) - "Currentevidence suggests that preoperative exposure to anti-TNF agents, vedolizumab, or ustekinumab doesnot substantially increase postoperative infectious complications. Postoperative management should rely on objective monitoringrather than symptoms alone, as endoscopic recurrence frequently precedes clinical relapse.Ileocolonoscopy at 6–12 months after resection remains the cornerstone of postoperative monitoringand guides subsequent treatment optimization. Ultimately, achieving durable remission requires close collaboration between gastroenterologists andcolorectal surgeons throughout the disease course, integrating appropriate biologic therapy, timelysurgery, perioperative optimization, and postoperative recurrence prevention."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. (PubMed, RMD Open) - "ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies."

Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A

Drug Similarity Network Model for Personalized Biologic Sequencing in Inflammatory Bowel Disease - A Novel Undirected Weighted Similarity-Graph Framework (ACG 2026) - "Eight therapeutic classes were represented as network nodes: anti-TNF agents (infliximab, adalimumab), vedolizumab, ustekinumab, risankizumab, mirikizumab, ozanimod, and JAK inhibitors (tofacitinib, filgotinib), with similarity metrics derived from clinical remission, endoscopic healing, biomarker normalization, and safety outcomes. The calibrated network identified ustekinumab as a key bridging therapy after anti-TNF failure in Crohn's disease (CD). Key similarity scores included: vedolizumab-anti-TNF (0.68), ustekinumab-risankizumab (0.78), ustekinumab-vedolizumab (0.72), and anti-TNF-ozanimod (0.55). In anti-TNF-experienced CD, the model prioritized risankizumab over ustekinumab, consistent with SEQUENCE trial findings (endoscopic remission at week 48: 31.8% vs 16.2%, p< 0.0001)."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Early Experience With Etrasimod in Ulcerative Colitis Patients: A Claims Database Study in the United States (ACG 2026) - "(e)Advanced treatments: adalimumab, golimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, tofacitinib, upadacitinib, and ozanimod. A total of 297 patients were included (mean age, 47.3 years [SD, 17.5]; 52.2% male), and 127 comprised the follow-up population. In the follow-up population, most patients were AT-naïve (67.7%), and 48.0% had used steroids within 24 weeks prior to index date (Table 1). Through week 24, median adherence was 89.8% (quartile 1: 53.9%; quartile 3: 98.8%), and 59.1% of patients had PDC â¥0.80."

Claims database • Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety of Inadvertent Live Vaccine Administration in Patients With Inflammatory Bowel Disease on Immune-Modifying Therapy (ACG 2026) - "The exposed cohort comprised IBD patients who received a live vaccine (measles, mumps, and rubella (MMR), varicella, measles, mumps, rubella, and varicella (MMRV)...Inclusion required a vaccine CPT code, â¥12 months of continuous enrollment prior to index date, an IBD diagnosis (â¥2 IBD-related outpatient visits), and a prescription for an immune-modifying therapy (anti-tumor necrosis factor (TNF), vedolizumab, ustekinumab, tofacitinib, upadacitinib, risankizumab, guselkumab, or mirikizumab) < 90 days of the index date...³Anti-TNF agents: infliximab, adalimumab, certolizumab, golimumab...6Immunomodulators: methotrexate, azathioprine, 6-mercaptopurine... 220 IBD patients met inclusion criteria for the live vaccine cohort (132 MMR, 73 varicella, 15 MMRV); 170 (77%) were on anti-TNF therapy and 30 (14%) on vedolizumab (Figure). The comparator group comprised 2,204 PCV13 recipients Table for baseline demographics. All-cause hospitalization or ED..."

Clinical • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Measles • Mumps • Pneumococcal Infections • Rubella • Varicella Zoster • IL23A

Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report. (PubMed, Cureus) - "Clinical improvement was achieved after restarting ustekinumab and methotrexate. This case highlights the potential for dupilumab to trigger severe paradoxical psoriasis in patients with pre-existing psoriatic disease. Clinicians should remain vigilant when prescribing dupilumab in this population, and early recognition with prompt modification of therapy may lead to favorable clinical outcomes."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Efficacy of Janus Kinase Inhibitors for Immune Checkpoint Inhibitor Colitis: A Case Series (ACG 2026) - "Prior biologics included IFX (n=3), VDZ (n=4), and ustekinumab (n=1)...Three patients received upadacitinib and 2 received tofacitinib...Larger prospective studies are needed to evaluate earlier JAKi introduction in this population. Figure: Table 1: Characteristics of 5 patients with refractory ICI-C treated with JAKi Immune checkpoint inhibitor colitis (ICI-C), yes/no (Y/N), common terminology criteria for adverse events (CTCAE), fecal calprotectin (FC), C-reactive protein (CRP), mayo endoscopic score (MES), janus kinase inhibitor (JAKi), infliximab (IFX), vedolizumab (Vedo), Usetkinumab (Ustek), not available (NA), to be determined (TBD), deceased (DCSD)."

Checkpoint inhibition • Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Lung Adenocarcinoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor • Venous Thromboembolism • CRP

Risk of Incident Melanoma With TNF-Alpha Inhibitor Therapy in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study (ACG 2026) - " Using the TriNetX U.S. Collaborative Network, we identified adults â¥18 years with IBD who initiated TNFi on or before February 7, 2024; controls initiated mesalamine or a non-TNFi biologic (ustekinumab, vedolizumab, risankizumab, mirikizumab, or guselkumab). Patients with prior melanoma or melanoma in situ; exposure to opposite-class advanced therapy, JAK inhibitors (tofacitinib, upadacitinib), thiopurines (azathioprine, mercaptopurine, thioguanine), or methotrexate before or within 5 years after index were excluded... In TNFi vs mesalamine, 21,848 matched pairs (mean age 38.9 ± 17.9 years; 51.1% female sex; 78.0% White) accrued mean follow-up of 2.5 years (median 3.0 years). There was no statistically significant difference in incident melanoma (0.10% vs 0.08%; OR 1.22, 95% CI 0.66â2.28; P=0.53) or composite outcome (0.11% each; OR 1.04, 0.59â1.82; P=0.89). Melanoma in situ alone was not separately reportable in this comparison due to small..."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Melanoma • Solid Tumor

Prevalence and Predictors of Fatigue in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study With Subgroup Analysis of Quiescent Disease (ACG 2026) - "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed FACIT-F; 201 (93.5%) had classifiable IBD clinical activity (69 active, 132 quiescent) and included in the analysis. Moderate-severe fatigue affected 82 (38.1%) overall; 44.9% in active and 33.3% in quiescent disease (50% in those with elevated biomarkers) (Figure 1A). On univariate analysis, moderate-severe fatigue was associated with HBI (p=0.034), CRP (p=0.03), poor sleep (PSQIâ¥5; p< 0.001), depression (HADS-D â¥8; p< 0.001) and anxiety (HADS-A â¥8; p< 0.001) (Table 1)."

CNS Disorders • Crohn's disease • Depression • Fatigue • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • CRP

Prevalence and Outcomes of Hormone Therapy Use Among Menopausal Women With Inflammatory Bowel Disease (ACG 2026) - "However, patients with CD prescribed systemic HT had higher oral prednisone use, while osteoporosis/fracture outcomes were lower among patients receiving systemic HT. Figure: 1-Systemic non-transdermal HRT included oral estradiol, conjugated estrogens, esterified estrogens, synthetic conjugated estrogens A and B, oral progesterone, oral medroxyprogesterone, conjugated estrogens/bazedoxifene (Duavee), estradiol acetate vaginal ring (Femring), and norethindrone acetate/ethinyl estradiol (Femhrt). 2-Systemic transdermal HRT included estradiol/norethindrone acetate transdermal patch (CombiPatch), estradiol/levonorgestrel transdermal patch (Climara Pro), estradiol transdermal patches (Alora, Climara, Dotti, Estraderm, Lyllana, Minivelle, Vivelle-Dot), estradiol transdermal gel (EstroGel, Divigel), and estradiol transdermal spray (Evamist). 3-Local estrogen therapy included low-dose vaginal estradiol formulations (Estring, Imvexxy, Vagifem, and Yuvafem) and vaginal conjugated..."

Clinical • Cardiovascular • Coronary Artery Disease • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pulmonary Embolism • Respiratory Diseases • Ulcerative Colitis

Medically Refractory Acute Severe Ulcerative Colitis Complicated by Cytomegalovirus Managed With Diverting Loop Ileostomy During Pregnancy: A Case Report (ACG 2026) - "Case Description/ A 23-year-old woman with a 10-year history of ulcerative pancolitis being treated with upadacitinib 45mg and prednisone 40mg was transferred from another hospital at 25 weeks gestation with 2 weeks of bloody diarrhea. She had loss of response or non-response to adalimumab, vedolizumab, ustekinumab, and prior response to infliximab induction but lost response after switching to subcutaneous maintenance...Intravenous solumedrol was started on day 1 and upadacitinib was continued...She continued infliximab and valganciclovir and tapered off prednisone outpatient...Secondly, the management of CMV colitis during pregnancy may differ from non-pregnant individuals, as ganciclovir is typically avoided due to potential risks to the fetus...Figure: Figure 1: Representative image from flexible sigmoidoscopy showing severe colitis with erythema and ulcerations. Figure: Figure 2: Picture of the patientâs ostomy wound two weeks post-op."

Case report • Clinical • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Shiga Toxin-Producing E. coli Infection in Inflammatory Bowel Disease:Impact on Acute Complications and Disease Course (ACG 2026) - "Among those on immunomodulators, infliximab or vedolizumab, 7.44% switched therapy (ustekinumab 5.79%, risankizumab 1.65%). We identified 625 IBD patients with STEC infection: 345 with Crohn's disease (CD) and 280 with ulcerative colitis (UC), as well as 96,605 non-IBD controls. Prior to infection, most of CD patients were on TNF inhibitors (57.50%), while most UC patients were on 5-ASA (71.60%). At 30 days, no significant differences were observed in rates of AKI (3.20% vs 2.88%; RR 1.11, 95% CI 0.59-2.08), severe outcomes (6.08% vs 5.92%; RR 1.03, 95% CI 0.66-1.59), antibiotic administration (6.56% vs 4.64%; RR 1.41, 95% CI 0.89-2.25), and hospitalization (7.36% vs 5.28%; RR 1.39, 95% CI 0.90-2.15)."

Acute Kidney Injury • Atypical Hemolytic Uremic Syndrome • Cardiovascular • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Crohn's disease • Diabetes • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Septic Shock • Thrombocytopenia • Ulcerative Colitis

Perioperative Safety Profile of IBD Medications: A Comparative Study of Real World Pharmacovigilance Data (ACG 2026) - "Golimumab showed elevated UC sepsis (1.88), whereas Adalimumab and Certolizumab showed lower CD sepsis (0.54, 0.27) and Adalimumab lower DVT and PE in both indications. Vedolizumab showed elevated UC DVT and PE (~1.5); natalizumab elevated CD PE (2.30); ustekinumab an isolated UC ileus signal (14.15)... Thiopurines and Methotrexate showed the most consistent signals across both indications: elevated ROR for sepsis (Azathioprine UC: ROR 2.03, CD: 1.85; Mercaptopurine UC: 2.64, CD: 2.04; Methotrexate UC: 1.57), DVT (Methotrexate UC 4.15, CD 2.33; Azathioprine CD 2.23, Mercaptopurine UC 2.29), and PE (Methotrexate UC 1.96; Azathioprine CD 1.84). Azathioprine UC also showed elevated anastomotic leak (7.15). Among anti-TNFs, infliximab showed elevated CD sepsis (2.12), DVT (1.90), and PE (1.82), as well as UC DVT (1.32)."

Adverse events • Clinical • Real-world • Real-world evidence • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Septic Shock • Ulcerative Colitis

Dual Biologic Therapy in a Pregnant Patient With Crohn's Disease and Axial Spondyloarthritis (ACG 2026) - "She had previous non-response to mesalamine, mercaptopurine, certolizumab pegol, adalimumab, infliximab, and upadacitinib, as well as combination therapy with upadacitinib and vedolizumab. She then achieved clinical remission with a combination of risankizumab and golimumab...Recent randomized trials showed improved rates of clinical remission in patients with ulcerative colitis and Crohnâs disease treated with dual therapy with guselkumab and golimumab compared to monotherapy...Data from the Pregnancy Inflammatory bowel disease And Neonatal Outcomes (PIANO) registry has shown no increased risk of pregnancy complications in patients treated with anti-TNF medications, immunomodulators, TNF/immunomodulator combination therapy, vedolizumab, and ustekinumab in patients with IBD. This case highlights emerging therapeutic strategies and the importance of patient centered multidisciplinary care for optimal pregnancy outcomes."

Clinical • Ankylosing Spondylitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Seronegative Spondyloarthropathies • Spondylarthritis • Ulcerative Colitis • CRP

Sustained Clinical and Endoscopic Improvements With up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderate to Severe Ulcerative Colitis Regardless of the Number of Prior Advanced Therapy Exposures (ACG 2026) - "AT included approved biologics for UC (infliximab, adalimumab, golimumab, ustekinumab, and/or vedolizumab), approved Janus kinase inhibitors for UC (tofacitinib, filgotinib, upadacitinib), and/or ozanimod. At induction baseline, among the 1003 pts included in the AO analysis, 29.4% (N=295) were AT-naïve; 29.4% (N=295) and 41.2% (N=418) had previously experienced 1 and >1 AT, respectively. Among the RZB180 and RZB360 groups, rates of CR (per AMS or PAMS) generally remained stable at OLE W0 and 96, regardless of the number of prior AT exposures, per AO analysis. Rates of endoscopic improvement and remission were sustained, regardless of the number of prior AT exposures, per AO analysis."

Clinical • Metastases • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2027 ➔ Jan 2028 | Initiation date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2027 ➔ Jan 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Orthopedics • Psoriatic Arthritis • Rheumatology

Pre-Existing Metabolic Dysfunction-Associated Steatotic Liver Disease as a Negative Modifier of Biologic Treatment Effectiveness in Inflammatory Bowel Disease: A Propensity Score-Matched Cohort Study (ACG 2026) - " We identified adults with Crohn's disease or ulcerative colitis who started a biologic (infliximab, adalimumab, vedolizumab, ustekinumab, or risankizumab) between 2017 and 2024 using the TriNetX Research network, a federated multi-institutional electronic health record. Among 34,318 eligible patients, 6,284 had MASLD. After matching, 5,972 patients were in each group. Patients with MASLD had significantly higher rates of treatment failure compared to those without MASLD (35.8% vs."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Ulcerative Colitis

Comparative Pancreatic Adverse Event Reporting of Non-TNF Biologics in Inflammatory Bowel Disease: A Layered FAERS Disproportionality Analysis, 2020-2025 (ACG 2026) - "IBD-indicated primary-suspect reports for vedolizumab, ustekinumab, risankizumab, mirikizumab, and guselkumab were compared across IBD-restricted, all-FAERS, withinânon-TNF, and anti-TNF comparator layers...Comparator choice altered estimates: against all FAERS, vedolizumab (ROR 1.56; A=252), risankizumab (1.16; A=244), and mirikizumab (2.73; A=5) were above unity, whereas active-comparator analysis highlighted the anti-TNF class (1.22, 1.07â1.39; A=586) and infliximab (1.60, 1.40â1.83; A=336). Among 1,624 valid onset pairs, Weibull shapes were < 1 for infliximab, vedolizumab, adalimumab, and ustekinumab... Of 8,439,854 deduplicated reports, 241,416 carried an IBD indication. There were 88,061 non-TNF and 116,292 anti-TNF primary-suspect IBD reports; 422 non-TNF IBD reports had a narrow pancreatic event. In the primary IBD-restricted analysis, no individual non-TNF biologic or class met the primary or conservative signal definition."

Adverse events • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pancreatic Cancer • Pancreatitis • Solid Tumor • IL12A • ROR1

Efficacy of Risankizumab Versus Other Advanced Therapies for Moderate to Severe Ulcerative Colitis in Advanced Therapy Naïve Populations: A Bayesian Network Meta-Analysis (ACG 2026) - " This NMA utilized published data from phase 3 randomized controlled trials of the following FDA-approved first-line ATs for moderate to severe UC: RZB, guselkumab (GUS), mirikizumab (MIR), ustekinumab (UST), vedolizumab (VDZ), golimumab (GOL), infliximab (IFX), adalimumab (ADA), etrasimod (ETR), and ozanimod (OZA). ITT efficacy rates of clinical remission and endoscopic improvement were highest for RZB (1200 mg x 360 mg) ( Figure ). GUS, MIR, and RZB (1200 mg x 180 mg) had the highest ITT rates for clinical response. In the Induction NMA, RZB demonstrated the highest odds ratio (OR [95% credible interval]) vs PBO for clinical response (5.12 [3.29-7.94]) and endoscopic improvement (5.32 [3.03-9.68])."

Metastases • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Ulcerative Colitis